Novel anti-HER2 antibody-drug conjugates versus T-DM1 for HER2-positive metastatic breast cancer after tyrosine kinase inhibitors treatment

According to data from an analysis of novel anti-HER2 antibody-drug conjugates (ADCs; including trastuzumab deruxtecan [T-Dxd]) versus trastuzumab emanstine (T-DM1) among patients with metastatic HER2-positive breast cancer that failed prior tyrosine kinase inhibitor therapy, T-Dxd and other novel anti-HER2 ADCs demonstrated statistically significant better PFS compared with T-DM1 (7.0 versus 4.0 months, respectively; HR 0. 43 [95% CI: 0.29-0.65], P < .0001), with tolerable toxicities.